Bispecific chimeric antigen receptors targeting CD20 and bcma
A bispecific CAR targeting CD20 and BCMA addresses the inadequacies of current autoimmune disease treatments by achieving deep B cell depletion and sustained remission in autoimmune diseases like systemic lupus erythematosus.
WO2026151675A1PCT designated stage Publication Date: 2026-07-16ABELZETA INC
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- PCT/US2026/010241
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-10-13
- Filing Date
- 2026-01-06
- Publication Date
- 2026-07-16
AI Technical Summary
Technical Problem
Current treatments for autoimmune diseases, such as systemic lupus erythematosus, are inadequate, with therapies like rituximab and obexelimab failing to meet primary endpoints, highlighting the need for more effective B cell depletion strategies.
Method used
Development of a bispecific chimeric antigen receptor (CAR) that targets both CD20 and BCMA, comprising specific antigen-binding regions and signaling domains, which can be administered to immune cells to enhance B cell depletion.
Benefits of technology
The bispecific CAR effectively depletes B cells, leading to sustained disease remission and reduced autoantibody production, as demonstrated by deep B cell depletion and drug-free remission in clinical trials.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure IMGF000009_0001 
Figure IMGF000024_0001 
Figure IMGF000026_0001
Abstract
The present disclosure provides bispecific chimeric antigen receptors targeting CD20 and BCMA. The CAR may comprise an scFv targeting CD20 and an scFv targeting BCMA, a hinge region, a transmembrane domain, a co-stimulatory region, and a cytoplasmic signaling domain. The chimeric antigen receptors can be used to treat autoimmune disorders or cancer.
Need to check novelty before this filing date? Find Prior Art